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NeurodegenerationAlzheimer's disease (AD) implies the presence of progressive cogni-
tive decline to the point an individual cannot manage their daily affairs
(dementia), in conjunction with intraneuronal accumulations of tau
protein (tangles) in deﬁned cortical regions and extracellular cortical
accumulations of beta amyloid protein (Aβ plaques). Our ability to
deﬁne AD does not mean we fully understand it; AD deﬁnitions them-
selves continue to evolve and disagreements over its causes remain
(Swerdlow, 2007). All agree, though, that better treatments are needed.
It is this need the study of Zhang et al. (published in this issue of
EBioMedicine) sought to address (Zhang et al., in press). Members of
this group previously reported a tricyclic pyrone compound, CP2,
ameliorated Aβ toxicity in a cell culture setting, reduced ﬁbrillary and
non-ﬁbrillar Aβ species in an AD transgenic mouse model, and in fact
directly bound Aβ (Zhang et al., in press). Observations reported in
the current study by Zhang, Trushina, and colleagues, though, indicate
that this compound's biological effects transcend its ability to directly
bind Aβ.
Through a series of elegant experiments, it was deduced that CP2
competitively occupies the ﬂavin mononucleotide (FMN) redox site
within complex I, a respiratory chain holoenzyme on themitochondrial
innermembrane, thereby inhibiting its function. Unlike other complex I
inhibitors, CP2-mediated complex I inhibition does not seem to induce
oxidative stress or inﬂammation, perhaps by limiting the initial entryDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.03.009.
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ratory chain oxygen consumption it also concomitantly increases respi-
ratory coupling, a measure of how efﬁciently the respiratory chain
converts electron energy to ATP. It creates a mild energy stress, which
appears to activate AMP kinase (AMPK), a protein that monitors and
responds to cell energy states, promotes cell resiliency under stress con-
ditions, and inhibits the glycogen synthase kinase 3β (GSK3β) enzyme
that enhances tau phosphorylation. Other changes observed in CP2-
treated mice or neuronal cultures from mice that express a mutated
human amyloid precursor protein (APP) transgene, a mutated human
presenilin 1 (PS1) transgene, or both included reduced tau phosphory-
lation, improved axon transport, increased brain derived neurotrophic
factor (BDNF) levels, altered APP processing, reduced plaque burden,
and perhaps most importantly preserved behavioral function. Presum-
ably, these effects represent downstream consequences of CP2-altered
respiratory chain function, CP2 binding to Aβ, or both.
This study has implications for the ﬁeld of aging research. Mitochon-
dria and energymetabolism inﬂuence aging, but this is not a straightfor-
ward relationship. Intact mitochondrial function and enhancing
respiration promote healthy aging and longevity in at least some
models (Trifunovic et al., 2004; Schulz et al., 2007). Consistent with
other reports, though, the Zhang et al. data argue inhibiting respiration
can also beneﬁt healthspan as CP2-treated mice in general seemed to
age better, with fecundity preserved until later ages, than untreated
mice. The Zhang et al. data are also consistent with the emerging recog-
nition that energy stress, as opposed to energy bounty, confers lifespan
and healthspan beneﬁts (Munkacsy and Rea, 2014) and may underlie
some reported beneﬁts of caloric restriction and physical exercise. The
paradoxical ability of energy stress to promote health and survival
may arise through an activation of mitochondria-associated stress
responses (Durieux et al., 2011).
The Zhang et al. study also provides insight into an increasingly
recognizedmitochondria-APP-Aβnexus. APP andAβ reportedly localize
to mitochondria, and may affect mitochondrial function, but mitochon-
drial function also modiﬁes APP processing (Swerdlow, 2012). This
latter phenomenon raises the possibility that CP2-mediated reductions
in ﬁbrillary Aβ deposition reﬂect altered mitochondrial function, as
opposed to a direct consequence of Aβ-binding. Of potential relevance
to this possibility is the study of Fukui et al. (2007), which found
preventing complex IV holoenzyme assembly, thereby limiting respira-
tion, also reduced Aβ deposition in APP/PS1 transgenic mice.
To date, numerous attempts to treat AD by removing Aβ, interfering
with Aβ aggregation steps, or directly altering APP have failed in humanthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ventions, trial design, or the amyloid cascade hypothesis, and has pro-
moted interest in alternative treatment strategies. One alternative
approach focuses onmanipulations of mitochondria and energymetab-
olism, both of which are altered in the brains of AD patients (Swerdlow,
2014). CP2 certainly qualiﬁes as an interesting mitochondrial and
bioenergetic medicine agent. By interfering with cell ATP production
and changing NAD+/NADH ratios the effects of CP2 extend beyond its
inhibition of complex I. In the Zhang et al. study examples of this
manifested through a variety of demonstrated effects such as AMPK
activation, reduced tau phosphorylation, and altered APP processing
but no doubt many downstream consequences remain to be shown.
Preclinical success in AD transgenic mouse models does not imply
that successful translation to human subjectswill occur. Overexpressing
mutant human transgenes in mice may poorly model the disorder or
disorders that characterize the vast majority of AD patients. This study
also assumed a “prevention” strategy, as CP2 was started before
histologic or pathologic changes developed in the mice; preventing
and treating AD may require different approaches. Regardless, the
study by Zhang et al. justiﬁes testing CP2 in human AD subjects. If AD
is indeed driven by Aβ, CP2 could impact the disease through direct
effects on that protein. Perhaps of greater interest, if altered APP homeo-
stasis and Aβ accumulation represent downstream consequences of
mitochondrial dysfunction and compromised brain bioenergetics
(Swerdlow et al., 2014), CP2 may impact the disease by acting on
the possible upstream causes of altered APP homeostasis and Aβ
accumulation.
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